← Leaderboards
Veronica Rodriguez-Bravo
Mayo Clinic Rochester
$4,467,659
Attributed
$5,452,488
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,452,488 · 5
By mechanism
R01$4,901,688 · 4
K22$550,800 · 1
Top collaborators
- Josep Maria Domingo-Domenech4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Josep Maria Domingo-Domenech$5,429,135
- Zhenkun Lou$18,569,951
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsGeneticGenesPathogenesisCell SurvivalResistanceEpigenetic ProcessPathway InteractionsTumorProstate Cancer CellTranscription FactorAndrogen ReceptorTherapy ResistantChromatinGenetic TranscriptionMalignant Neoplasm Of ProstateLinkPost-Translational Protein ProcessingAdvanced Prostate CancerPre-ClinicalNovel Therapeutic InterventionNuclear Pore Complex ProteinsMitotic
Grant awards (17)
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors$532,649
R01 · FY2025 · CA
Investigating the impact of chromosomal instability on prostate cancer aggressiveness$485,354
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer$452,180
R01 · FY2025 · CA
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors$532,649
R01 · FY2024 · CA
Investigating the impact of chromosomal instability on prostate cancer aggressiveness$485,354
R01 · FY2024 · CA · contact PI
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer$452,180
R01 · FY2024 · CA
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$370,612
R01 · FY2024 · CA · contact PI
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$384,875
R01 · FY2023 · CA · contact PI
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$352,912
R01 · FY2022 · CA · contact PI
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$30,358
R01 · FY2022 · CA · contact PI
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$379,454
R01 · FY2021 · CA · contact PI
Role of nuclear pore-regulated mechanisms in prostate cancer aggressiveness$63,657
R01 · FY2021 · CA · contact PI
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness$379,454
R01 · FY2020 · CA · contact PI
Genome Stability Regulation by the Nuclear Pore-Chromosome Axis and Defects in Tumor Cells$183,600
K22 · FY2018 · CA · contact PI
Genome Stability Regulation by the Nuclear Pore-Chromosome Axis and Defects in Tumor Cells$123,811
K22 · FY2017 · CA · contact PI
Genome Stability Regulation by the Nuclear Pore-Chromosome Axis and Defects in Tumor Cells$59,789
K22 · FY2017 · CA · contact PI
Genome Stability Regulation by the Nuclear Pore-Chromosome Axis and Defects in Tumor Cells$183,600
K22 · FY2016 · CA · contact PI